NCT04665232View on ClinicalTrials.gov

Immunomodulatory Effects of Subcutaneous Progesterone in Patients Affected by Autoimmune Diseases

CompletedOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Autoimmune DiseasesInfertility
Interventions
DRUG

aqueous subcutaneous progesterone

25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.

Trial Locations (1)

85100

Assunta Iuliano, Potenza

All Listed Sponsors
lead

San Carlo Public Hospital, Potenza, Italy

OTHER

NCT04665232 - Immunomodulatory Effects of Subcutaneous Progesterone in Patients Affected by Autoimmune Diseases | Biotech Hunter | Biotech Hunter